Biotest AG — Capital/Financing Update 2005

Sep 6, 2005

News Details

Ad-hoc | 6 September 2005 10:19

Biotest AG increases capital stock by up to EUR 3.9 million

Ad hoc announcement §15 WpHG Capitalization Biotest AG increases capital stock by up to EUR 3.9 million Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Biotest AG increases capital stock by up to EUR 3.9 million Dreieich, September 6, 2005. Today, with the approval of the Supervisory Board, Biotest AG’s Board of Management resolved to increase the company’s share capital by up to EUR 3.9 million. Biotest intends to use the proceeds from the capital increase to fast-track several projects that are particularly important in implementing the group’s strategy – such as the clinical development of therapeutic monoclonal antibodies, the development of new indications and forms of application for plasma derivatives and to bolster its international sales organisation. Up to 856,525 new ordinary shares and up to 666,667 preferred shares are to be issued and offered to Biotest AG’s shareholders for subscription as part of the capital increase. The Supervisory Board today agreed to the capital increase, which utilises the company’s Authorised Capital. The capital increase will be supported by Commerzbank AG, Frankfurt am Main, and Landesbank Baden-Württemberg, Stuttgart, as syndicate banks. The details of the capital increase, such as the subscription ratio, the subscription price and the subscription period will be defined and published soon, immediately prior to the subscription offer being published, by way of a separate resolution and depending on the current market position. Investor Relations: Hubert Bötsch, Telephone: +49 (0) 6103 801-444, Telefax: +49 (0) 6103 801-880, E-mail: hubert_boetsch@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, http://www.biotest.de WKN (German Securities Code), ISIN ordinary shares: 522720, DE0005227201 WKN (German Securities Code), ISIN preferred shares: 522723, DE0005227235 Listed: Amtlicher Handel in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg and Stuttgart Biotest AG Landsteinerstraße 5 63303 Dreieich Deutschland ISIN: DE0005227201; DE0005227235 WKN: 522720; 522723 Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart End of ad hoc announcement (c)DGAP 06.09.2005 061019 Sep 05